Skip to content
drillr.ai

CTSO

Cytosorbents Corporation

NASDAQ · USHealthcareMedical - Devices
$0.38+5.58%

Price as of Jul 20, 2026

CTSO news

Cytosorbents Corporation news

A server-rendered, paginated timeline of the latest available company news.

  1. Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

    NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24(th) & 25(th) Life Sciences Virtual Investor Forum are now available for on-demand viewing. REGISTER AND VIEW PRESENTATIONS HERE (https://www.globenewswire.com/Tracker?data=b6dnU6dvUGjThc6TpC6iNVaL_5rZR9ziA3ts2JBqVGEztObcLrsjy1_aMH9uE_ZQ7s73xllM4muIbRmK24BrAwQpLxBLTs3UwTftRdPPpZu6pBVL8j9kK_c167_huoujPoz3AFWKIfZ9uTMZaAOKLH

    Globe Newswire ·

  2. CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026

    PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (https://www.globenewswire.com/Tracker?data=TaHt_w_o1PTPT1PGgr8XRWvctrmbUAKrOfoW-U1XfasYPhoB1rHwyUKQfp7_iI1K-niOUy_itEmrSHE8UoWusncfj2GJ6DBxDNue8DnQge8=) (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the Life Sciences Forum hosted by VirtualInvestorC

    Globe Newswire ·

  3. CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

    CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update PR Newswire PRINCETON, N.J., May 13, 2026 PRINCETON, N.J., May 13, 2026 /PRNewswire/ -- CytoSorbents Corporation (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4688270-1&h=2389745047&u=http%3A%2F%2Fwww.cytosorbents.com%2F&a=CytoSorbents+Corporation) (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purif

    PR Newswire ·

  4. CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

    CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights PR Newswire PRINCETON, N.J., March 25, 2026 * 2025 revenue of $37.1 million, up 4% year-over-year, and 71% Full-year gross margins * Enhanced Balance Sheet Flexibility with an Additional $2.5 million Proceeds from Amended Credit Facility in November * Implemented Strategic Workforce and Cost Reduction Program in Q4 to Accelerate Timing to Cash Flow Breakeven in 2026 * Ongoing Interactive Discu

    PR Newswire ·

  5. CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026

    CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 PR Newswire PRINCETON, N.J., March 19, 2026 PRINCETON, N.J., March 19, 2026 /PRNewswire/ -- CytoSorbents Corporation (https://edge.prnewswire.com/c/link/?t=0&l=en&o=4645340-1&h=3598143325&u=http%3A%2F%2Fwww.cytosorbents.com%2F&a=CytoSorbents+Corporation) (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood p

    PR Newswire ·